PureTech Health (LON:PRTC) Reaches New 12-Month Low – Here’s What Happened

Shares of PureTech Health plc (LON:PRTC) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 138 ($1.68) and last traded at GBX 143 ($1.75), with a volume of 1221521 shares. The stock had previously closed at GBX 140 ($1.71).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 455 ($5.56) price target on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Price Performance

The company has a market cap of £335.19 million, a P/E ratio of -608.70 and a beta of 1.02. The company’s 50-day moving average price is GBX 161.04 and its two-hundred day moving average price is GBX 162.44. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 47.27.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.